Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $1.014 million which beat the analyst consensus estimate of $700.000 thousand by 44.86 percent. This is a 90.56 percent decrease over sales of $10.739 million the same period last year.